Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study. Issue 1 (16th February 2021)

• Record Type: Journal Article
• Authors: Ramonda, Roberta; Lorenzin, Mariagrazia; Carriero, Antonio; Chimenti, Maria Sole; Scarpa, Raffaele; Marchesoni, Antonio; Lubrano, Ennio; Salvarani, Carlo; Cauli, Alberto; Semeraro, Angelo; Santo, Leonardo; Ortolan, Augusta; Doria, Andrea; Fracassi, Elena; Virelli, Giulia; Masia, Marco; Fanizzi, Rosalinda; Visalli, Elisa; Amato, Giorgio; Carletto, Antonio; Foti, Rosario
• Other Names: author non-byline.; Scarpa Raffaele author non-byline.; Marchesoni Antonio author non-byline.; Salvarani Carlo author non-byline.; d'Angelo Salvatore author non-byline.; Cauli Alberto author non-byline.; Lubrano Ennio author non-byline.; Ramonda Roberta author non-byline.; Carriero Antonio author non-byline.; Chimenti Maria Sole author non-byline.; Semeraro Angelo author non-byline.; Santo Leonardo author non-byline.; Lorenzin Mariagrazia author non-byline.; Ortolan Augusta author non-byline.; Doria Andrea author non-byline.; Fracassi Elena author non-byline.; Virelli Giulia author non-byline.; Masia Marco author non-byline.; Fanizzi Rosalinda author non-byline.; Visalli Elisa author non-byline.; Amato Giorgio author non-byline.; Carletto Antonio author non-byline.; Foti Rosario author non-byline.; Costa Luisa author non-byline.; Francesca Desiati author non-byline.; Fonti Giulia Lavinia author non-byline.; Girolimetto Nicolò author non-byline.; Perrotta Fabio Massimo author non-byline.; Praino Emanuela author non-byline.
• Is Part Of: RMD open. Volume 7:Issue 1(2021)
• Publication Date: 2021-02-16
• Subjects: arthritis -- psoriatic -- antirheumatic agents -- biological therapy; Musculoskeletal system -- Diseases -- Periodicals; Rheumatism -- Periodicals; 616.7005
• DOI: 10.1136/rmdopen-2020-001519
• Languages: English
• ISSNs: 2056-5933

Abstract

Abstract : Objectives: To evaluate in a multicentric Italian cohort of patients with psoriatic arthritis (PsA) on secukinumab followed for 24 months: (1) the long-term effectiveness and safety of secukinumab, (2) the drug retention rate and minimal disease activity (MDA), (3) differences in the outcomes according to the biological treatment line: biologic-naïve patients ( group A ) versus multifailure ( group B ) patients. Methods: Consecutive patients with PsA receiving secukinumab were evaluated prospectively. Disease characteristics, previous/ongoing treatments, comorbidities and follow-up duration were collected. Disease activity/functional/clinimetric scores and biochemical values were recorded at baseline (T0), 6(T6), 12(T12) and 24(T24) months. Effectiveness was evaluated overtime with descriptive statistics; multivariate Cox and logistic regression models were used to evaluate predictors of drug-discontinuation and MDA at T6. Infections and adverse events were recorded. Results: 608 patients (41.28% men; mean (SD) age 52.78 (11.33)) were enrolled; secukinumab was prescribed as first-line biological treatment in 227 (37.34%) patients, as second (or more)-line biological treatment in 381 (62.66%). Effectiveness of secukinumab was shown with an improvement in several outcomes, such as Ankylosing Spondylitis Disease Activity Score (T0=3.26 (0.88) vs T24=1.60 (0.69) ;p=0.02) and Disease Activity Index for Psoriatic Arthritis (T0=25.29 (11.14) vs T24=7.69 (4.51); p<0.01). At T24, group A showed lower Psoriasis Area Severity Index (p=0.04), erythrocyte sedimentation rate and C reactive protein (p=0.03 ;p=0.05) and joint count (p=0.03) compared with group B . At T24, MDA was achieved in 75.71% of group A and 70.37% of group B . Treatment was discontinued in 123 (20.23%) patients, mainly due to primary/secondary loss of effectiveness, and in 22 due to adverse events. Retention rate at T24 was 71% in the whole population, with some difference depending on secukinumab dosage (p=0.004) and gender (p=0.05). Conclusions: In a real-life clinical setting, secukimumab proved safe and effective in all PsA domains, with notable drug retention rate.